Patient Stratification

The DNA microarray technology applied in molecular biology makes it possible to rapidly diagnose disease at the molecular level. In the development of gene based diagnoses, bioinformatics applications and development of new software tools already play a pivotal role. In addition, it enables us to identify new pathways and indicators of disease prognosis to predetermine one’s genetic risk and to design novel therapeutic agents. In the near future, treatments will be increasingly tailored to the individual’s genome.

Bioinformaticians from Erasmus MC use Next Generation Sequencing technology from Complete Genomics to study genetic variations at a higher resolution and greater sensitivity than previously possible. With DNA sequencing getting cheaper more quickly than data storage or computation, the time has come for genome informatics to migrate to the cloud and use shared datacenters.

‘Determining a gene expression profile for patients suffering from acute myeloid leukemia can contribute to more effective and more specific treatment. With the aid of the powerful new GeneChip technology a robust prognostic genetic profile can be derived in patients with acute myeloid leukemia. This is the conclusion of researchers of the Department of Hematology and Bioinformatics of Erasmus MC on an article which had appeared in the April 15, 2004 edition of The New England Journal of Medicine’.



(Valk et al, N Engl J Med. 2004 apr 15;350 (16):1617-28)

The discovery of clinically applicable gene signatures and DNA variants from cancer cells in AML patients led to the founding of Skyline Diagnostics in 2005. The investigators and clinicians of the Departments of Hematology and Bioinformatics of the Erasmus University  Medical Center, among whom professor Bob Löwenberg and professor Peter van der Spek teamed up with biotech entrepreneur Henk Viëtor, PhD, to develop that discovery into a powerful clinical tool: the AMLprofiler. Since its inception, the company has perfected the AMLprofiler and filled its pipeline with other, promising new profilers. Making use of the GeneChip® Technology as an official Powered-by-Affymetrix partner, Skyline takes microarray technology to a whole new level by helping clinicians fight cancer better. In recent years, we expanded and became a company of over twenty ambitious people motivated to make personalized medicine a reality in oncology.

 

Visit http://www.skyline-diagnostics.com for more information

 

Dr. Molewaterplein 50, Suite Ee-1540, 3015 GE Rotterdam. The Netherlands, Europe. Phone: +31 (0)10 70 43 491. Fax: +31 (0)10 70 44 161. E-mail: bioinformatics@erasmusmc.nl